Lorvotuzumab mertansine Completed Phase 1 Trials for Multiple Myeloma (MM) Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00346255BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
NCT00991562IMGN901 in Combination With Lenalidomide and Dexamethasone